Full Year
NEUP — FY2026 Annual Report Analysis (Year Ended June 30, 2026)
Neuphoria's Phase 3 AFFIRM-1 failure ended its lead programme, R&D spending fell 60.6% and a $5.4M goodwill writedown followed Merck's termination of the MK-1167 Alzheimer's trial — leaving a one-employee company with $19.9M of cash being sold to Scancell at a $24.6M valuation.